Kura Oncology to Participate in Upcoming Investor Conference

Rhea-AI Summary

Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the UBS Virtual Oncology Day. The management presentation is scheduled for October 1, 2025, at 2:30 p.m. ET.

Investors can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.

News Market Reaction – KURA

+1.70%

+1.70% Session close to close

In the Sep 24 session, KURA gained 1.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference.

UBS Virtual Oncology Day
Wednesday, October 1, 2025
2:30 p.m. ET / 11:30 a.m. PT

A live audio webcast will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with an archived replay available following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts

Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When is Kura Oncology (KURA) presenting at the UBS Virtual Oncology Day?

Kura Oncology will present at the UBS Virtual Oncology Day on October 1, 2025, at 2:30 p.m. ET / 11:30 a.m. PT.

How can investors access Kura Oncology's UBS Virtual Oncology Day presentation?

Investors can access the live audio webcast through the Investors section of Kura's website at kuraoncology.com. An archived replay will be available after the event.

What type of company is Kura Oncology (KURA)?

Kura Oncology is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment.

Will there be a replay available of Kura Oncology's UBS presentation?

Yes, an archived replay of the presentation will be available on Kura's website following the event.